ABIVAX Société Anonyme
ABVXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic. The $7.70B market capitalization puts ABVX squarely in mid-cap range for its industry. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Market Cap
$7.70B
Beta
-0.23
P/E (TTM)
—
P/E (Fwd)
-22.95
EPS (TTM)
$-6.08
EPS (Fwd)
$-3.84
ROE
-252.3%
ROA
-62.9%
Cash
$402.4M
Total Debt
$1.2M
Free CF
-$125.9M
52W Change
-7.2%
Annual Financials
Cash vs Debt
Where ABVX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, ABVX finished 23.06% below its 150-day moving average ($114.55) and 23.89% below its 200-day moving average ($115.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABVX overbought or oversold?
At the October 19, 2026 close, ABVX's RSI(14) was 35.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $402.4M in cash comfortably exceeding the $1.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$125.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -252.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, ABIVAX Société Anonyme typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ABVX.